课题基金 / 基金详情

Targeting a Poor Prognosis Marker for Tumor Therapy

Targeting a Poor Prognosis Marker for Tumor Therapy
针对肿瘤治疗的不良预后标志
批准号:
7999984
负责人:
Douglas A Lappi
金额:
$15.05万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2011-06-30

项目摘要

项目成果

Douglas A Lappi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Targeting a Poor Prognosis Marker for Tumor Therapy Summary The purpose of this proposal is to develop a medical treatment for the elimination of metastatic cancers. According to the National Cancer Institute, the survival rate for many types of cancer has improved in recent years; however, it is still the second leading cause of death in the United States. This proposal describes an experimental design to verify the suitability of basigin-2 (also known as CD147 or EMMPRIN) as a cell surface target for an innovative tumor therapy. This project will accomplish important goals in determining the suitability of basigin-2 for further drug development: 1) Provide proof of internalization of the target moiety (basigin-2) by using an antibody to basigin-2, and 2) Demonstrate that there is specificity, both in terms of greater ability to target the tumor over normal (lower level) expression and that anti-basigin is specific for the target. In this Phase I grant, a cytotoxin will be produced that has two components: 1) anti-basigin to specifically target and internalize into basigin-2 positive cells, and 2) a toxin that will inhibit protein synthesis upon internalization by the antibody. This innovative approach will create a molecule that targets tumor cells, metastasis and angiogenesis, with the idea to not just slow tumor cell proliferation, but to eliminate tumors. PUBLIC HEALTH RELEVANCE: Targeting a Poor Prognosis Marker for Tumor Therapy Narrative This project begins a new direction of potential treatment for a wide range of deadly cancers by targeting a molecule that is expressed on the surface of many tumor types with poor prognosis. While it is proposed to directly target these tumors through targeting the molecule, basigin-2, targeting of tumor metastasis and angiogenesis is also indicated, since basigin-2 plays important roles in those dangerous processes. The project builds on current technologies, but puts several together to go in a new, innovative direction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancing CRISPR-based Therapeutic Interventions Via a Targeted Platform Tool
  • 批准号:
    9253170
  • 项目类别:
  • 资助金额:
    $15.0万
  • 财政年份:
    2017
  • 负责人:
    Douglas A Lappi
  • 依托单位:
Development of a Novel Cancer Pain Therapeutic
  • 批准号:
    7928286
  • 项目类别:
  • 资助金额:
    $300.0万
  • 财政年份:
    2010
  • 负责人:
    Douglas A Lappi
  • 依托单位:
Selective Activation in Specific Neuronal Populations
  • 批准号:
    7538504
  • 项目类别:
  • 资助金额:
    $9.92万
  • 财政年份:
    2009
  • 负责人:
    Douglas A Lappi
  • 依托单位:
Inhibition of Neurotransmission in Specific Neuronal Populations
  • 批准号:
    7482543
  • 项目类别:
  • 资助金额:
    $11.43万
  • 财政年份:
    2008
  • 负责人:
    Douglas A Lappi
  • 依托单位:
国内基金
海外基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    32170319
  • 项目类别:
    面上项目
  • 资助金额:
    58.00万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
  • 批准号:
    --
  • 项目类别:
    --
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    董春海
  • 依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
  • 批准号:
    31372080
  • 项目类别:
    面上项目
  • 资助金额:
    80.0万元
  • 批准年份:
    2013
  • 负责人:
    杨迎伍
  • 依托单位: